Newsletter Tool

PM Tracker

Today’s Big News

Apr 5, 2024

As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model

Sanofi begins 'full pipeline reprioritization' with layoffs in tow, R&D chief tells staff

Johnson & Johnson adds Shockwave Medical to its cardiovascular collection with $13.1B deal

AbbVie retains ad spending leadership, but some surprise drugs make the top 10 in March

Bristol Myers’ Abecma wins FDA nod in earlier multiple myeloma with updated boxed warning on secondary cancer

Contineum lowers expectations for $110M IPO as J&J-allied biotech goes public

AstraZeneca’s Imfinzi tackles another type of lung cancer with latest trial win

Featured

As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model

By Fraiser Kansteiner

Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S. and adopt a different way of marketing its Humira biosimilar.

Sanofi begins 'full pipeline reprioritization' with layoffs in tow, R&D chief tells staff

By Max Bayer

Sanofi is laying off staff around the globe following a 'full pipeline reprioritization,' according to an email from R&D chief Houman Ashrafian to staff. The communication, obtained by Fierce Biotech, refer to a large-scale restructuring to afford late-stage drug development.

Johnson & Johnson adds Shockwave Medical to its cardiovascular collection with $13.1B deal

By Conor Hale

J&J MedTech sees Shockwave’s devices for cracking open calcified arteries as the ticket to its 13th billion-dollar platform.

AbbVie retains ad spending leadership, but some surprise drugs make the top 10 in March

By Ben Adams

It’s as you were at the top of the pharma drug ad spending list in March as AbbVie’s immunology blockbusters Rinvoq and Skyrizi stay first and second, respectively.

Bristol Myers’ Abecma wins FDA nod in earlier multiple myeloma with updated boxed warning on secondary cancer

By Angus Liu

After a short period of doubt, the FDA has followed the opinion of its advisers and moved Bristol Myers’ CAR-T therapy Abecma into the earlier treatment of multiple myeloma. The new nod also comes with an updated boxed warning and a wider dosing range.

Contineum lowers expectations for $110M IPO as J&J-allied biotech goes public

By James Waldron

Contineum Therapeutics has lowered its IPO expectations as the Johnson & Johnson-partnered biotech prepares to make the jump to the public markets this morning.

AstraZeneca’s Imfinzi tackles another type of lung cancer with latest trial win

By Angus Liu

AstraZeneca's Imfinzi has delivered positive clinical data in another type of lung cancer, building on the immunotherapy’s existing FDA clearance in stage 3 non-small cell lung cancer and extensive-stage small cell lung cancer.

Bayer honors Trans Day of Visibility by highlighting work to protect LGBTQ+ workers

By Andrea Park

As it works toward improving the diversity of its workforce, Bayer took a moment this week to celebrate some of the diverse voices already on board—and its own efforts to uphold their rights.

Novartis finally ready for Pluvicto filing in earlier prostate cancer as patient survival data clear up

By Angus Liu

After two delays spanning over a year, Novartis is finally gearing up for a high-stakes FDA application to expand the radiotherapy Pluvicto into earlier treatment of prostate cancer. But will the FDA bite?

Fierce podcasts

Don’t miss an episode

The unrecognized threat of PAD

This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged.

'The Top Line': The top money raisers in biotech

‘Podnosis’: How the arts can improve our health

Resources

Whitepaper

Oncology Market Outlook 2024

This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Guidance for Biotechs Choosing Next-Gen Contract GMP/CMC Labs

Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future.

PPD®️ Laboratory Services